The Effect of Pretransplant Chronic Hepatitis C Virus Infection Treatment on Graft and Patient Survival in Renal Transplant Recipients

dc.contributor.authorKorkmaz, Murat
dc.contributor.authorFaki, Sevgul
dc.contributor.authorOcal, Serkan
dc.contributor.authorHarmanci, Ozgur
dc.contributor.authorEnsaroglu, Fatih
dc.contributor.authorSelcuk, Haldun
dc.contributor.authorHaberal, Mehmet
dc.contributor.orcID0000-0002-3462-7632en_US
dc.contributor.orcID0000-0002-8445-6413en_US
dc.contributor.orcID0000-0002-9333-782Xen_US
dc.contributor.orcID0000-0003-3719-9482en_US
dc.contributor.orcID0000-0002-0643-4980en_US
dc.contributor.pubmedID25894152en_US
dc.contributor.researcherIDAAJ-8097-2021en_US
dc.contributor.researcherIDAAJ-6976-2021en_US
dc.contributor.researcherIDAAM-1330-2020en_US
dc.contributor.researcherIDABH-4817-2020en_US
dc.date.accessioned2024-02-09T10:40:52Z
dc.date.available2024-02-09T10:40:52Z
dc.date.issued2015
dc.description.abstractObjectives: Studies have demonstrated worse graft and patient survival among hepatitis C virus-positive patients following kidney transplant. Eradication of hepatitis C virus infection before renal transplant with interferon should be considered in hepatitis C virus-infected patients undergoing dialysis who are on the waiting list for transplant. We investigated whether pretransplant hepatitis C virus infection treatment affected graft and patient survival, and we evaluated other contributing factors to these outcomes. Materials and Methods: We enrolled 83 antihepatitis C virus-positive patients who were diagnosed with chronic hepatitis C virus infection by serology or histopathology and had renal transplant at Baskent University Ankara Hospital from 1982 to 2013. Data were obtained from patient medical files retrospectively. Patients were divided into 2 groups that had or did not have interferon treatment. Results: In 83 renal transplant patients with chronic hepatitis C virus infection (57 male [69%] and 26 female [31%]), median age was 46 years (range, 26 - 69 y), and most patients were genotype 1-dominant (92%). Interferon monotherapy was received by 30 patients before renal transplant and 28 of 30 patients had long-term follow-up data. There were 14 of 28 patients (50%) who achieved sustained virologic response, and only 1 patient had relapse. Graft survival was significantly lower in patients who had treatment (6 y vs 9 y; P <= .003). However, patient survival rates were similar between groups. Patients who had interferon were younger and had longer hemodialysis duration before renal transplant than patients without treatment. Higher viral load was associated with higher mortality which was caused by sepsis. Conclusions: Pretransplant hepatitis C virus infection treatment, although recommended before renal transplant, does not always have good outcomes. Pretransplant dialysis treatment period, age of recipient, and posttransplant higher viral replication rates may be important contributing factors related to graft and patient survival.en_US
dc.identifier.eissn2146-8427en_US
dc.identifier.endpage192en_US
dc.identifier.issn1304-0855en_US
dc.identifier.issueSupplement 1en_US
dc.identifier.scopus2-s2.0-84939788671en_US
dc.identifier.startpage188en_US
dc.identifier.urihttp://hdl.handle.net/11727/11468
dc.identifier.volume13en_US
dc.identifier.wos000355058400036en_US
dc.language.isoengen_US
dc.relation.isversionof10.6002/ect.mesot2014.O157en_US
dc.relation.journalEXPERIMENTAL AND CLINICAL TRANSPLANTATIONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEnd-stage renal diseaseen_US
dc.subjectInterferonen_US
dc.subjectOutcomesen_US
dc.titleThe Effect of Pretransplant Chronic Hepatitis C Virus Infection Treatment on Graft and Patient Survival in Renal Transplant Recipientsen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: